Real-world experience of inclisiran prescription at the University of Pennsylvania Health Systems

Real-world experience of inclisiran prescription at the University of Pennsylvania Health Systems

•85 % of patients prescribed inclisiran received insurance approval.•Patients with Medicare were more likely to obtain approval.•Patients new to PCSK9-targeted therapy observed reduction in LDL-C of 49 %.•60 % of patients with ASCVD achieved LDL-C level of

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical lipidology 2024-07
Hauptverfasser: Wei, Nicole M., Tobin, Robert F., Jacoby, Douglas S., Bajaj, Archna
Format: Artikel
Sprache:eng
Schlagworte:
Inclisiran
Low-density lipoprotein cholesterol
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor
siRNA
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•85 % of patients prescribed inclisiran received insurance approval.•Patients with Medicare were more likely to obtain approval.•Patients new to PCSK9-targeted therapy observed reduction in LDL-C of 49 %.•60 % of patients with ASCVD achieved LDL-C level of
ISSN:1933-2874
DOI:10.1016/j.jacl.2024.07.008